Please login to the form below

Not currently logged in

Sanofi submits MS drug Lemtrada for approval in EU and US

Once-yearly treatment will challenge both Merck KGaA’s Rebif and Novartis' Gilenya if approved

Sanofi has submitted its multiple sclerosis (MS) treatment Lemtrada (alemtuzumab) for regulatory approval in both the US and EU.

The France-based pharma company, which gained rights to the drug after its $20.1bn acquisition of Genzyme, has filed applications to both the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the drug's use in the treatment of relapsing MS.

If approved, Bayer Healthcare, which co-developed the drug with Genzyme, will retain an option to co-promote Lemtrada, although Sanofi would have primary responsibility for its development and commercialisation.

The drug is expected to do well if it makes it to market, with its yearly dosing regimen giving it an advantage over treatments that have to be taken more often, such as Merck KGaA's Rebif (interferon beta-1a).

The drug has also demonstrated superior efficacy to Rebif in clinical trials, achieving a 49 per cent reduction in relapse rates compared to Rebif in the CARE-MS II trial.

In addition, Lemtrada met the second of its co-primary end points, cutting the risk of sustained worsening of disability by 42 per cent compared to Rebif.

Sanofi's main competition is expected to come from Novartis' oral MS drug Gilenya (fingolimod), however, with the drug having been available in the US since 2010.

This is despite a recent update to the label of Novartis' drug to remove its approval for use in patients with a history of heart disease or stroke, after completing a review of the drug's safety. It is also contraindicated in patients taking anti-arrhythmic drugs.

Despite such competition, Dr David Meeker, president and CEO of Genzyme, was still confident of the Lemtrada's success: “There remains a large unmet treatment need for patients living with active disease and we believe that Lemtrada, given its efficacy and unique dosing schedule, has the potential to transform the lives of patients with multiple sclerosis.”

The success of the drug is key for Sanofi in its attempt to deal with several major patent losses that are set to hit revenues hard in 2012.

In its financial results for 2011, the company said it expects €1.4bn to be knocked off its net income for 2012 due to generic competition for its blood thinner Plavix and hypertension treatment Avapro.

13th June 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively....